List With HCPCS Codes For Miscellaneous Medical Services

The HCPCS codes for Miscellaneous Medical Services M0075-M0301 cover a range of medical procedures and treatments, including cellular therapy, prolotherapy, intragastric hypothermia, vaccine administration at home, and injection and monitoring for pre-exposure prophylaxis and covid-19 treatment.

1. HCPCS Code M0075

HCPCS M0075 describes the use of cellular therapy for medical treatment.

2. HCPCS Code M0076

HCPCS M0076 refers to prolotherapy, a treatment method that involves injecting a solution into damaged or weakened ligaments or tendons to promote healing.

3. HCPCS Code M0100

HCPCS M0100 represents the use of intragastric hypothermia using gastric freezing as a medical procedure.

4. HCPCS Code M0201

HCPCS M0201 covers the administration of pneumococcal, influenza, hepatitis B, and/or COVID-19 vaccines inside a patient’s home.

5. HCPCS Code M0220

HCPCS M0220 describes the injection of tixagevimab and cilgavimab for pre-exposure prophylaxis in individuals with compromised immune systems or severe adverse reactions to other COVID-19 vaccines.

6. HCPCS Code M0221

HCPCS M0221 refers to the injection of tixagevimab and cilgavimab for pre-exposure prophylaxis in individuals with compromised immune systems or severe adverse reactions to other COVID-19 vaccines, administered in the home or residence.

7. HCPCS Code M0222

HCPCS M0222 represents the intravenous injection of bebtelovimab, including post-administration monitoring.

8. HCPCS Code M0223

HCPCS M0223 describes the intravenous injection of bebtelovimab, including post-administration monitoring, administered in the home or residence.

9. HCPCS Code M0240

HCPCS M0240 covers the intravenous infusion or subcutaneous injection of casirivimab and imdevimab, including post-administration monitoring, for subsequent repeat doses.

10. HCPCS Code M0241

HCPCS M0241 refers to the intravenous infusion or subcutaneous injection of casirivimab and imdevimab, including post-administration monitoring, for subsequent repeat doses administered in the home or residence.